编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

5月14日，诺华创新药物信倍立（盐酸阿思尼布片）获得国家药品监督管理局批准，用于治疗新诊断的费城染色体阳性的慢性髓细胞白血病（Ph+CML）慢性期（CP）成人患者。作为全球首个且目前唯一获批基于ABL肉豆蔻酰口袋（STAMP）创新机制的靶向药物，阿思尼布可实现深度缓解率翻倍和不良事件相关停药风险减半，延缓疾病进展，为 ...

Oncoguide System: A computerized interactive assistance system for the diagnosis and treatment of CML/MPN and MDS D. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract ...

Phase II study of Sorafenib (BAY 43–9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research—EWIV (CESAR) This is an ASCO Meeting ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...